Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TRV130A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TRV130A | EXPERIMENTAL | - |
| Dextrose in Water | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TRV130A | DRUG | Intravenous infusion of 1 hour duration |
| Dextrose in Water | DRUG | Intravenous infusion of 1 hour duration |
Inclusion Criteria: * Healthy adult male 19 - 50 years of age * Body weight \>/= 50 kg * Capable of giving written informed consent Exclusion Criteria: * Clinically significant disease or conditions that may place the subject at unacceptable risk as a participant in the study, or that may interfe...
TRV130A is an investigational small molecule being studied in healthy volunteers. It is being developed by Trevena, Inc. for potential therapeutic use, though its specific target indication has not been established. The drug is currently in early-stage clinical development.
TRV130A is being developed by Trevena, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TRVN. The company is conducting clinical research on this investigational small molecule.
TRV130A is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The drug is being studied in healthy volunteers to assess its safety and tolerability.
TRV130A has one completed Phase 1 clinical trial, identified as NCT01514578. This was a single ascending dose study of intravenous TRV130A in healthy adult males, conducted in the United States with 74 participants.
TRV130A is an investigational drug being developed by Trevena, Inc. It is a small molecule that has been studied in healthy volunteers. No alternative names for this drug have been disclosed in the available clinical trial information.